Skip to main content
Image coming soon

GEN2208 Decision Rigor in Drug Candidate Selection

$200.00
Adding to cart… The item has been added

What is the Decision Rigor in Drug Candidate Selection course about?

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which experimental compounds to advance into clinical trials based on preclinical data. Each order is checked and updated against the latest insights before delivery. That is why access.

What does the Decision Rigor in Drug Candidate Selection cover on decision Rigor in Drug Candidate Selection?

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which experimental compounds to advance into clinical trials based on preclinical data. Each order is checked and updated against the latest insights before delivery. That is why access.

What does the Decision Rigor in Drug Candidate Selection cover on the situation this is built for?

You’re reviewing stacks of preclinical data, efficacy in disease models, off-target binding, metabolic stability, rodent toxicity, and you have to decide which molecule gets millions more in investment and moves into human testing. The data is incomplete. Teams disagree. The chemistry team sees promise. The toxicology team sees red flags. There’s no consistent way to weigh trade-offs. And when a compound fails later, everyone.

Who is the Decision Rigor in Drug Candidate Selection course for?

Chief scientific officer in a biotech or pharmaceutical company, responsible for aligning discovery and development functions to select clinical candidates from preclinical portfolios.

What do you take away from the Decision Rigor in Drug Candidate Selection course?

Apply a structured evaluation framework to preclinical candidate data Standardize go/no-go criteria across discovery and development teams Document and justify advancement decisions with traceable rationale Reduce late-stage attrition due to flawed early-stage decisions Lead candidate review meetings with clarity and confidence.

How does this map to your situation?

When preclinical data is conflicting or incomplete When cross-functional teams disagree on advancement When leadership demands clearer justification for decisions When past compound failures trace back to flawed selection.

What's included with your purchase?

12 modules with 12 chapters each (144 chapters) Downloadable templates and worked examples for every module Hand-built implementation playbook delivered alongside course access 30-day money-back guarantee.

What does the Decision Rigor in Drug Candidate Selection cover on delivery and format?

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access. Time investment: Approximately 36 hours of structured learning, designed for busy leaders to complete in 12 weeks at about 3 hours per week.

Closely related courses: Therapeutic Candidate Selection.

More answers: what you get with every course, refund policy, all help answers.

Page updated 2026-10-27.

The Executive Diagnostic and Governance Toolkit

Decision Rigor in Drug Candidate Selection

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which experimental compounds to advance into clinical trials based on preclinical data.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
Too many compounds fail just after advancement—because the decision to move forward wasn’t rigorous enough.

The situation this is built for

You’re reviewing stacks of preclinical data—efficacy in disease models, off-target binding, metabolic stability, rodent toxicity—and you have to decide which molecule gets millions more in investment and moves into human testing. The data is incomplete. Teams disagree. The chemistry team sees promise. The toxicology team sees red flags. There’s no consistent way to weigh trade-offs. And when a compound fails later, everyone asks: why did we advance this one? The decision was made under pressure, without structure, and now it’s costing time and credibility.

Who this is for

Chief scientific officer in a biotech or pharmaceutical company, responsible for aligning discovery and development functions to select clinical candidates from preclinical portfolios.

Who this is not for

Scientists focused only on assay development or preclinical execution without decision-making authority over compound progression.

What you walk away with

  • Apply a structured evaluation framework to preclinical candidate data
  • Standardize go/no-go criteria across discovery and development teams
  • Document and justify advancement decisions with traceable rationale
  • Reduce late-stage attrition due to flawed early-stage decisions
  • Lead candidate review meetings with clarity and confidence

How this maps to your situation

  • When preclinical data is conflicting or incomplete
  • When cross-functional teams disagree on advancement
  • When leadership demands clearer justification for decisions
  • When past compound failures trace back to flawed selection

Before vs. after

Before
Decisions are made reactively, data is interpreted inconsistently, and justification relies on advocacy rather than structure.
After
Advancement decisions follow a documented, repeatable process with clear criteria, shared understanding, and defensible rationale.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 36 hours of structured learning, designed for busy leaders to complete in 12 weeks at about 3 hours per week.

If nothing changes
Without structured decision frameworks, organizations advance compounds based on incomplete data and subjective interpretation—leading to higher attrition, wasted resources, and loss of stakeholder trust when candidates fail for foreseeable reasons.

How this compares to the alternatives

Unlike general project management or leadership courses, this program focuses specifically on the technical, organizational, and regulatory dimensions of compound advancement decisions—giving you actionable tools used in successful drug development organizations.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. The Anatomy of a Compound Advancement Decision
Break down the components of a high-stakes decision to move a molecule forward.
12 chapters in this module
  1. Understanding the scope of candidate selection decisions
  2. Mapping stakeholders in the compound advancement process
  3. Identifying critical data types in preclinical packages
  4. Differentiating lead optimization from candidate nomination
  5. Recognizing decision points in discovery timelines
  6. Defining what 'advancement' means in your organization
  7. Evaluating the role of regulatory strategy in selection
  8. Assessing portfolio context in individual decisions
  9. Balancing innovation with developability constraints
  10. Documenting assumptions behind early-stage data
  11. Anticipating downstream implications of selection
  12. Creating a decision charter for candidate nomination
Module 2. Evaluating Pharmacological Evidence Across Models
Assess the strength and relevance of efficacy data from in vitro and in vivo systems.
12 chapters in this module
  1. Interpreting dose-response curves in functional assays
  2. Assessing target engagement in cellular systems
  3. Evaluating translational relevance of animal models
  4. Weighing efficacy magnitude against model limitations
  5. Determining durability of pharmacological effect
  6. Analyzing pharmacodynamic biomarker consistency
  7. Handling discordant results across species
  8. Judging biological significance beyond statistical significance
  9. Assessing mechanism-based versus off-target efficacy
  10. Incorporating patient-derived data into model evaluation
  11. Evaluating functional redundancy in pathway assays
  12. Documenting confidence in pharmacology package
Module 3. Toxicology Risk Assessment in Preclinical Packages
Systematically evaluate safety signals and project human risk.
12 chapters in this module
  1. Interpreting histopathology findings in rodent studies
  2. Assessing dose-dependency of adverse events
  3. Evaluating safety margins across species
  4. Identifying organ-specific toxicity patterns
  5. Judging reversibility of observed toxicities
  6. Assessing relevance of rodent-specific findings
  7. Analyzing genotoxicity assay results
  8. Weighing cardiovascular safety signals
  9. Integrating immunotoxicity data into risk profile
  10. Evaluating reproductive toxicity flags
  11. Projecting human safety based on animal data
  12. Creating a tiered safety risk classification
Module 4. Pharmacokinetics and Exposure Considerations
Interpret ADME data to predict human dosing and exposure.
12 chapters in this module
  1. Analyzing plasma concentration-time profiles
  2. Assessing bioavailability across species
  3. Interpreting metabolic stability assays
  4. Evaluating drug-drug interaction potential
  5. Assessing tissue distribution patterns
  6. Predicting human clearance from preclinical data
  7. Determining half-life implications for dosing
  8. Evaluating protein binding effects on efficacy
  9. Analyzing metabolite profiles for safety
  10. Assessing formulation feasibility from solubility data
  11. Projecting human exposure using allometric scaling
  12. Integrating PK/PD modeling into selection
Module 5. Developability and Physicochemical Profiling
Assess molecular properties that impact manufacturability and stability.
12 chapters in this module
  1. Interpreting solubility and permeability data
  2. Assessing chemical stability under stress conditions
  3. Evaluating crystallinity and polymorph risks
  4. Analyzing lipophilicity and its implications
  5. Determining molecular weight and size constraints
  6. Assessing synthetic complexity and route scalability
  7. Evaluating salt and co-crystal options
  8. Interpreting pKa and logD profiles
  9. Assessing potential for aggregation in solution
  10. Analyzing formulation development challenges
  11. Evaluating cold chain requirements
  12. Documenting developability risk flags
Module 6. Target Validation and Biological Rationale
Evaluate the strength of evidence linking target to disease.
12 chapters in this module
  1. Assessing human genetic evidence for target
  2. Evaluating functional validation in model systems
  3. Analyzing tissue expression patterns in disease
  4. Assessing pathway context and redundancy
  5. Evaluating competitive landscape for target
  6. Interpreting patient biopsy data relevance
  7. Assessing target tractability for modulation
  8. Evaluating safety implications of target biology
  9. Analyzing biomarker strategy for target engagement
  10. Weighing novelty versus validation in target choice
  11. Assessing duration of target modulation needed
  12. Documenting confidence in target hypothesis
Module 7. Cross-Functional Data Integration
Synthesize inputs from discovery, DMPK, and toxicology into a unified assessment.
12 chapters in this module
  1. Aligning timelines across preclinical functions
  2. Creating integrated study evaluation templates
  3. Facilitating joint data review sessions
  4. Resolving conflicting interpretations across teams
  5. Assigning cross-functional ownership of data gaps
  6. Developing shared definitions for risk categories
  7. Integrating data into candidate comparison matrices
  8. Documenting rationale for resolving discrepancies
  9. Establishing escalation paths for unresolved issues
  10. Using joint scoring systems for compound ranking
  11. Maintaining version control of integrated data
  12. Preparing consolidated dossiers for review
Module 8. Designing Candidate Review Meetings
Structure high-functioning decision forums with clear inputs and outputs.
12 chapters in this module
  1. Defining roles and responsibilities in review meetings
  2. Creating standardized data presentation formats
  3. Setting decision rules for advancement
  4. Designing decision record templates
  5. Managing advocacy bias in team discussions
  6. Structuring time for data review versus debate
  7. Incorporating silent review before discussion
  8. Facilitating balanced participation from functions
  9. Setting thresholds for go/no-go decisions
  10. Documenting dissenting opinions and minority views
  11. Archiving decisions for regulatory readiness
  12. Evaluating meeting effectiveness over time
Module 9. Risk-Benefit Analysis Framework
Apply a structured method to weigh potential benefits against safety and developability risks.
12 chapters in this module
  1. Defining therapeutic need magnitude
  2. Assessing potential clinical differentiation
  3. Estimating probability of technical success
  4. Weighing safety risks against unmet need
  5. Incorporating patient risk tolerance into assessment
  6. Evaluating competitive clinical landscape
  7. Assessing commercial viability implications
  8. Using scoring systems for benefit-risk balance
  9. Incorporating regulatory precedent into risk tolerance
  10. Analyzing combination therapy potential
  11. Projecting development pathway complexity
  12. Documenting rationale for risk acceptance
Module 10. Decision Triggers and Thresholds
Define clear, measurable criteria for advancement and termination.
12 chapters in this module
  1. Setting minimum efficacy thresholds
  2. Defining safety margin requirements
  3. Establishing pharmacokinetic benchmarks
  4. Creating developability pass-fail criteria
  5. Setting target product profile alignment
  6. Evaluating fit with portfolio strategy
  7. Defining data sufficiency for progression
  8. Setting termination triggers for toxicity
  9. Creating go/no-go decision trees
  10. Applying thresholds consistently across programs
  11. Documenting rationale for threshold exceptions
  12. Reviewing thresholds after compound failure
Module 11. Documentation and Regulatory Readiness
Ensure decisions are traceable, auditable, and defensible to regulators.
12 chapters in this module
  1. Creating a candidate nomination dossier
  2. Documenting data gaps and assumptions
  3. Recording decision rationale with timestamps
  4. Archiving raw data references
  5. Linking decisions to study reports
  6. Ensuring traceability from assay to advancement
  7. Preparing for regulatory questions on selection
  8. Documenting risk mitigation plans
  9. Maintaining version history of evaluations
  10. Standardizing terminology in decision records
  11. Aligning documentation with ICH guidelines
  12. Preparing for inspection of selection process
Module 12. Building Organizational Decision Capability
Scale rigorous decision making across programs and teams.
12 chapters in this module
  1. Training teams on evaluation frameworks
  2. Onboarding new members to decision standards
  3. Conducting post-mortems on failed candidates
  4. Updating criteria based on new data
  5. Scaling frameworks across therapeutic areas
  6. Integrating external collaboration data
  7. Maintaining decision framework version control
  8. Auditing consistency in application
  9. Sharing best practices across programs
  10. Evolving thresholds with platform learning
  11. Incorporating regulatory feedback into process
  12. Measuring impact of decision rigor on attrition

Frequently asked

Who is this course designed for?
It is designed for chief scientific officers and senior leaders accountable for selecting clinical candidates from preclinical data packages.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does this cover regulatory submission content?
It covers how to document decisions for regulatory readiness, but does not address IND or equivalent dossier preparation.
Are there live components or is it self-paced?
The course is entirely self-paced with text-based content, downloadable resources, and a tailored implementation playbook.
Will I learn to use specific software or platforms?
No. The course focuses on decision frameworks, evaluation criteria, and organizational practices—not technology tools.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 36 hours of structured learning, designed for busy leaders to complete in 12 weeks at about 3 hours per week..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.
!